Well Referenced

Tag: Rapamycin

Chronic Rapamycin Restores Brain Vascular Integrity and Function Through NO Synthase Activation and Improves Memory in Symptomatic Mice Modeling Alzheimer’s Disease

This 2013 study investigated the effects of chronic rapamycin treatment in transgenic mice exhibiting Alzheimer’s-like symptoms. Administered after symptom onset, rapamycin significantly restored cerebral blood flow, increased vascular density, reduced amyloid plaque accumulation, and minimized microhemorrhages. These effects were mediated by activation of endothelial nitric oxide synthase (eNOS), enhancing nitric

Read More »
June 26, 2025 No Comments

A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects

This 2018 pilot study assessed the safety and feasibility of daily 1 mg rapamycin administration over 8 weeks in 25 healthy older adults aged 70–95. The treatment was generally well-tolerated, with minor adverse events including facial rash, stomatitis, and gastrointestinal discomfort. Notably, there were statistically significant reductions in erythrocyte parameters

Read More »
June 26, 2025 No Comments

Long-lasting Geroprotection from Brief Rapamycin Treatment in Early Adulthood by Persistently Increased Intestinal Autophagy

This 2022 study published in Nature Aging demonstrates that a brief course of rapamycin treatment in early adulthood induces persistent activation of intestinal autophagy, leading to extended lifespan and improved gut barrier function in Drosophila and mice. Notably, the geroprotective effects were comparable to those seen with lifelong rapamycin administration,

Read More »
June 26, 2025 No Comments

mTOR Inhibitors for Treatment of Low-Risk Prostate Cancer

This 2018 hypothesis article proposes that low-dose mTOR inhibition, particularly with rapamycin, may slow the progression of low-grade prostate cancer, enabling patients to remain on active surveillance and avoid or delay definitive treatments like surgery or radiation. The rationale is based on mTOR’s role in cellular senescence and immunomodulation, especially

Read More »
June 26, 2025 No Comments

Rapamycin and Ageing: When, for How Long, and How Much?

This 2014 review by Matt Kaeberlein evaluates critical variables in rapamycin use for aging interventions, including optimal dosing, treatment duration, and initiation timing. While rapamycin consistently extends lifespan in animal models, most studies employ a standard dose and continuous administration, potentially missing more effective strategies. Emerging evidence suggests intermittent or

Read More »
June 26, 2025 No Comments

Compounds that Extend Longevity Are Protective in Neurodegenerative Diseases and Provide a Novel Treatment Strategy for These Devastating Disorders

This 2020 review examines the therapeutic potential of longevity-extending compounds—metformin, rapamycin, resveratrol, N-acetyl-L-cysteine (NAC), and curcumin—in neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and ALS. These compounds modulate aging-related cellular pathways that contribute to neurodegeneration, including mitochondrial dysfunction, oxidative stress, protein aggregation, and chronic inflammation. Each agent demonstrates neuroprotective effects

Read More »
June 26, 2025 No Comments

Koschei the Immortal and Anti-Aging Drugs

This 2014 review by Mikhail V. Blagosklonny draws parallels between the Slavic folklore figure Koschei the Immortal and modern anti-aging strategies. The article posits that Koschei’s lean and ageless appearance could be attributed to mechanisms similar to those activated by calorie restriction (CR) and pharmacological agents like rapamycin. CR is

Read More »
June 26, 2025 No Comments

Still Living Better through Chemistry: An Update on Caloric Restriction and Caloric Restriction Mimetics as Tools to Promote Health and Lifespan

This 2020 review explores how caloric restriction (CR) and caloric restriction mimetics (CRMs) enhance healthspan and lifespan through modulation of key nutrient-sensing pathways, including IGF-1, mTOR, and AMPK. CR has been associated with improved metabolic parameters, reduced inflammation, and extended lifespan in multiple species. CRMs—such as resveratrol, metformin, and rapamycin—aim

Read More »
June 26, 2025 No Comments

Aging and Immortality: Quasi-Programmed Senescence and Its Pharmacologic Inhibition

This 2006 review by Mikhail V. Blagosklonny introduces the “quasi-programmed” theory of aging, proposing that aging is an unintended continuation of developmental growth programs driven by pathways like mTOR. These hyperfunctional processes lead to age-related diseases and functional decline. The paper suggests that pharmacological inhibition of these pathways, particularly using

Read More »
June 26, 2025 No Comments